Retrospective evaluation of short-term forecast performance of ensemble sub-epidemic

frameworks and other time-series models: The 2022-2023 mpox outbreak across multiple

geographical scales, July 14th, 2022, through February 26th, 2023

Amanda Bleichrodt*[1], Ruiyan Luo[1], Alexander Kirpich[1], Gerardo Chowell[1]

[1] Department of Population Health Sciences, School of Public Health, Georgia State University,

Atlanta, GA, USA.

* Corresponding author

Email: ableichrodt1@student.gsu.edu

Abstract

In May 2022, public health officials noted an unprecedented surge in mpox cases in non-endemic countries worldwide. As the epidemic accelerated, multi-model forecasts of the epidemic's trajectory were critical in guiding the implementation of public health interventions and determining policy. As the case levels have significantly decreased as of early September 2022, evaluating model performance is essential to advance the growing field of epidemic forecasting.

Using laboratory-confirmed mpox case data from the Centers for Disease Control and Prevention (CDC) and Our World in Data (OWID) teams through the week of January 26th, 2023, we generated retrospective sequential weekly forecasts (e.g., 1-4-weeks) for Brazil, Canada, France, Germany, Spain, the United Kingdom, the USA, and at the global scale using models that require minimal input data including the auto-regressive integrated moving average (ARIMA), general additive model (GAM), simple linear regression (SLR), Facebook's Prophet model, as well as the sub-epidemic wave (spatial-wave) and n-sub-epidemic modeling frameworks. We assess forecast performance using average mean squared error (MSE), mean absolute error (MAE), weighted interval score (WIS), 95% prediction interval coverage (95% PI coverage), and skill scores. Average Winkler scores were used to calculate skill scores for 95% PI coverage.

Overall, the n-sub-epidemic modeling framework outcompeted other models across most locations and forecasting horizons, with the unweighted ensemble model performing best across all forecasting horizons for most locations regarding average MSE, MAE, WIS, and 95% PI coverage. However, many locations had multiple models performing equally well for the average 95% PI coverage. The n-sub-epidemic and spatial-wave frameworks improved considerably in

39   average MSE, MAE, and WIS, and Winkler scores (95% PI coverage) relative to the ARIMA

40   model. Findings lend further support to sub-epidemic frameworks for short-term forecasting

41   epidemics of emerging and re-emerging infectious diseases.

Summary

In the face of many unknowns (i.e., transmission, symptomology) posed by the unprecedented 2022-2023 mpox epidemic, near real-time short-term forecasts of the epidemic's trajectory were essential in intervention implementation and guiding policy. As case levels continue to dissipate, evaluating the modeling strategies used in producing real-time forecasts is critical to refine and grow the field of epidemiological forecasting. Here, we systematically evaluate the performance of an ensemble n-sub-epidemic and related sub-epidemic wave (spatial-wave) modeling frameworks against ARIMA, GAM, Prophet, and SLR models in producing sequential retrospective weekly (1-4 week) forecasts of mpox cases for the highest burdened countries (i.e., Brazil, Canada, France, Germany, Spain, the United Kingdom, and the United States) and on a global scale. Overall, the n-sub-epidemic framework outperformed all other models most frequently, followed closely in success by the spatial-wave framework, GAM, and ARIMA models regarding average MSE, MAE, and WIS metrics. The n-sub-epidemic unweighted model and spatial-wave framework performed best overall based on average 95% PI coverage, and we noted widespread success for both frameworks in average Winkler scores. The considerable success seen with both frameworks highlights the continued utility of sub-epidemic methodologies in producing short-term forecasts and their potential application to other epidemiologically different diseases.

Introduction

Over the past year, an unprecedented global surge in mpox cases has affected multiple countries previously free of the disease [1,2]. Early on, little was known regarding critical transmission

and control factors – vaccination, the role of asymptomatic individuals, and transmission

pathways – which shaped the overall epidemic trajectory [3,4]. For example, a majority of mpox

cases in the current epidemic have occurred via close intimate and sexual contact, mainly in the

gay, bisexual, and men who have sex with men (MSM) communities [5–10], whereas in past

outbreaks and in endemic countries, this was not the case [7,11,12]. Therefore, as mpox cases

increased in late July 2022, our team started to produce and make publicly available weekly

short-term forecasts of new cases for the highest-affected countries (e.g., Brazil, Canada, France,

Germany, Spain, the United Kingdom, and the United States) and at the global level employing

semi-mechanistic growth models [13–16], which have shown past forecasting success in the

context of emerging infectious disease [16–18].

For any emerging pathogen that rapidly transmits throughout a population, short-term forecasts

of the epidemic's trajectory at different spatial scales can help guide policy and intervention

strategies [8,19–22]. However, there is little opportunity to assess forecasting performance and

improve models amid an ongoing public health crisis. Fortunately, as of September 2022, cases

have steadily declined worldwide [1,23–25], with non-endemic countries reporting 88,696 cases

and 142 deaths overall as of October 11th, 2023 [26]. Therefore, as we continue into the declining

phase of the epidemic, a retrospective evaluation of employed forecasting methodologies is vital

to preparing for future public health events.

While over 108 countries experienced unprecedented levels of mpox cases, Brazil, Canada,

France, Germany, Spain, the United Kingdom, and the United States saw the largest spike in

confirmed cases during the initial wave of the epidemic [1,16]. Nevertheless, each country saw

variable epidemic trajectories, with the United States facing the highest burden of cases, and

Brazil experiencing the most prolonged peak (~8-weeks)[1,26]. Canada, the United Kingdom,

and France saw multiple subsequent smaller peaks during the declining phase of the outbreak,

possibly due to a decrease in vaccine uptake [27,28], failure to receive the full vaccination

regiment (i.e., two doses) [27,28], or relaxation of preventative behaviors [1,20,28] (Fig A in S1

Appendix). Given the heterogeneous impact of the epidemic at different spatial scales, a

retrospective evaluation of multi-model forecasts is key for better understanding sub-epidemic

model performance in different contexts, which can contribute to advancing the science of

epidemic forecasting.

Several methodologies have been employed to forecast the case trajectory of the 2022-2023

mpox epidemic in various geographical regions, including, but not limited to, models focused on

human judgment [29], deep learning, and artificial intelligence models (AI)[30–32], machine

learning models [30–35], statistical models such as auto-regressive integrated moving average

(ARIMA) models [31,33–37], compartmental models [38], and semi-mechanistic sub-epidemic

models [16]. Performance metrics employed have mainly included variations of mean absolute

error (MAE) [16,30,31,33–35,37], mean squared error (MSE) [16,30–37], and mean absolute

percentage error (MAPE) [16,31,33–35], with only two studies also including probabilistic

measures of performance such as the weighted interval score (WIS) [16,39]. Of the studies

included here, four focused on the ascending phase of the epidemic (January 2022-Mid August

2022)[29,33,34,36], four evaluated forecasts of the ascending and peak of the epidemic

(February 2022-September 2022) [30–32,39], and four focused on the ascending, peak and

decline phases of the epidemic (January 2022-Present) [16,35,37,38].

In this paper, we carried out a comprehensive retrospective assessment of forecasting

performance (1-4 weeks ahead) of sub-epidemic modeling frameworks compared against other

commonly employed statistical models, including auto-regressive integrated moving average

models (ARIMA), general additive models (GAM), simple linear regression (SLR), and

Facebook's Prophet model (Prophet) for the most impacted countries. We focus on producing

and evaluating forecasts using the weeks of July 14th, 2022, through January 26th, 2023, for

model calibration, which captures the full epidemic trajectory in the countries of interest. We

considered a comprehensive set of performance metrics in the field of epidemic forecasting,

namely the mean absolute error (MAE), mean squared error (MSE), 95% prediction interval

coverage (95% PI), and weighted interval score (WIS).

Methods

Source Data

Our team utilized confirmed mpox cases from the highest-impacted countries (weeks of May 5th,

2022, through the week of January 26th, 2023) to produce and evaluate sequential retrospective

weekly forecasts (weeks of July 14th, 2022, through the week of February 23rd, 2023) from the

Centers for Disease Control (CDC) [40] and the Our World and Data (OWID) GitHub page [41].

We aggregated cases on the weekly level to ensure an adequate number of cases for the

forecasting process, and to control for daily reporting differences between locations. Both data

repositories employ different collection and reporting methodologies regarding their published

data. For example, the CDC team obtains mpox data from the CDC call center or their

emergency response common operating platform, DCIPHER, published weekly on Wednesdays

but is now updated monthly [40]. The OWID team uses data assembled by the World Health

Organization (WHO) from direct data reporting from WHO Member States and posts daily case

updates [9,41].

Both the CDC and the OWID team define a *confirmed case* as a laboratory-confirmed case (i.e.,

infection detected by polymerase chain reaction testing) [42,43], but define the date associated

with each case differently. The CDC defines the *onset date* as the earliest date available

regarding the case (i.e., symptom onset, diagnosis date, positive laboratory test date, or date

reported to the CDC)[40]. However, the OWID team defines *onset date* first as the date of

symptom onset. If symptom onset is unknown, they then employ the date of lab or clinical

diagnosis, followed by the date the case was reported [9].

Data Collection and Preparation

We obtained daily cases series published weekly from the CDC [40] and daily from the OWID

[41] team on August 9th, 2023, and August 15th, 2023, respectively. We then aggregated the data

to the weekly level, with a week starting on Thursday and ending on Wednesday, to avoid

calibrating the model with partial weeks of case data. Our team retrieved data for the United

States from both the CDC and OWID sources to explore differences in model performance in the

United States dependent on the data source used. Data on the global level and for the countries

that experienced the most significant outbreaks during the initial epidemic wave (i.e., Brazil,

Canada, France, Germany, Spain and the United Kingdom) were gathered only from the OWID

team [1].

Model calibration and forecasting strategy

Our analysis includes 12-models in total: the n-sub-epidemic framework (i.e., top-ranked,

second-ranked, weighted ensemble, unweighted ensemble), the sub-epidemic wave (spatial

wave) framework (i.e., top-ranked, second-ranked, weighted ensemble, unweighted ensemble), a

generalized additive model (GAM), a simple linear regression model (SLR), an auto-regressive

integrated moving average model (ARIMA), each with an assumption of normality, and

Facebook's Prophet model. Compared to a 9-week and 10-week calibration period, the 11-week

calibration period produced the best forecast performance overall. Therefore, the remainder of

this analysis employs an 11-week calibration period for all model fitting and forecasting. The full

sensitivity analysis comparing calibration period forecasting performance can be found in

supplementary file 2 (S2 Appendix).

For the week of July 14th, 2022, we could not produce forecasts for Canada for the n-sub-

epidemic framework due to the low case counts during the early phase of the epidemic. We also

could not produce forecasts for the week of July 14th, 2022, and July 21st, 2022, using the n-sub-

epidemic and spatial-wave frameworks for Brazil due to low case counts. Similarly, some model

calibration periods may be between 8 and 10 weeks long for the n-sub-epidemic and spatial-

wave frameworks as initial zeros (i.e., any zeros that proceed the calibration period) are

truncated until the first non-zero observation occurs.

Therefore, for each model and location, we conducted approximately 112 retrospective weekly

sequential 1- to 4-week forecasts, with forecasts spanning from the weeks of July 21st, 2022,

through the week of February 23rd, 2023. We primarily used 11-week calibration periods for

each location, with the forecast period date representing the first day of the week in which the

forecast was produced. Descriptions of the n-sub-epidemic and spatial-wave frameworks,

ARIMA, GAM, and Prophet methodologies are below. The SLR model included *time* as the only

predictor; therefore, its description is not included in further detail. Data posted in the week of

August 3rd, 2023, was used to produce and evaluate all forecasts.

The n-sub-epidemic modeling framework

The n-sub-epidemic framework employs multiple epidemic trajectories modeled as the

aggregation of overlapping and asynchronous sub-epidemics [17]. A sub-epidemic follows the 3-

parameter generalized-logistic growth model (GLM), which is given by the following:

$$\frac{dC(t)}{dt} = C'(t) = rC^p(t)\left(1 - \frac{C(t)}{K_0}\right),$$

196   (1)

where $C(t)$ denotes the cumulative mpox case count at time t and $\frac{dC(t)}{dt}$ describes the incidence

curve of mpox cases over time t. The parameter r, the growth rate per unit of time, remains

positive, and parameter K_0 represents the final outbreak size. The "scaling of growth" parameter

$p \in [0,1]$ allows the model to capture early sub-exponential and exponential growth patterns. If

$p = 0$, this equation describes a constant number of new cases over time, while $p = 1$ indicates

that the early growth phase is exponential. Intermediate values of p ($0 < p < 1$) describe early

sub-exponential (e.g., polynomial) growth dynamics. The GLM has displayed competitive

performance in the context of varying infectious diseases, including Zika, Ebola, and COVID-19

[44–47].

An n-sub-epidemic trajectory is comprised of n overlapping sub-epidemics and is given by the

following system of coupled differential equations:

$$\frac{dC_i(t)}{dt} = C_i{}'(t) = A_i(t) r_i C_i{}^{p_i}(t) \left(1 - \frac{C_i(t)}{K_{0_i}}\right),$$

208
(2)

where $C_i(t)$ tracks the cumulative number of cases for sub-epidemic i, and the parameters that

characterize the shape of the i_{th} sub-epidemic are given by (r_i, p_i, K_{0_i}), for $i = 1, \dots, n$. Here, n

represents the number of sub-epidemics considered in the epidemic's trajectory. When $n = 1$,

the sub-epidemic model is equivalent to the GLM above (1). However, when $n > 1$, we employ

the indicator variable, $A_i(t)$, to model the onset timing of the $(i + 1)_{th}$ sub-epidemic, where

$(i + 1) \leq n$. Therefore, the $(i + 1)_{th}$ sub-epidemic is triggered when the cumulative curve of the

i_{th} sub-epidemic exceeds the case threshold value, C_{thr} (i.e., $C_{thr} \leq K_{0_i}$). Thus, we have

216
$$A_i(t) = \begin{cases} 1, & C_{i-1}(t) > C_{thr} \\ 0, & Otherwise \end{cases} \quad for\ i = 2, \dots, n\,,$$

217
(3)

218   where $A_1(t) = 1$ for the first sub-epidemic. Therefore, $3n + 1$ parameters are needed to model an

219   n-sub-epidemic trajectory for $n > 1$. This analysis considers a maximum of two sub-epidemics

220   in the n-sub-epidemic trajectory ($n \leq 2$). The initial number of mpox cases is given by $C_1(0) =$

221   I_0, where I_0 is the initial number of cases in the observed data. The cumulative curve of the n-

222   sub-epidemic trajectory is given by:

$$C_{tot}(t) = \sum_{i=1}^{n} C_i(t).$$

223
(4)

Overall, the modeling framework can be applied to diverse epidemic patterns including those

characterized by multiple peaks and extended high-case level plateaus, similar to what has been

observed throughout the mpox epidemic (Fig A in S1 Appendix).

Parameter estimation for the *n*-sub-epidemic framework

Let the time series of new incident mpox cases used in model calibration be denoted as

$y_{t_1}, y_{t_2}, \ldots, y_{t_{n_d}}$ where $t_j, j = 1, 2, \ldots, n_d$, are the time points for the time series data, and n_d is the

number of observations. Using these case series, we estimated a total of $3n + 1$ model

parameters, namely $\Theta = \left(C_{thr}, r_1, p_1, K_{0_1}, \ldots, r_n, p_n, K_{0_n} \right)$ when n, the number of sub-epidemics,

is greater than 1. Let $f(t, \Theta)$ denote the expected curve of new mpox cases of the epidemic's

trajectory. We employed the nonlinear least squares (LSQ) method to estimate the model

parameters by fitting the model solution to the observed mpox data [48]. Specifically, we

considered different values of C_{thr} by simply discretizing its range of plausible values. For each

C_{thr}, we searched for the set of parameters $\hat{\Theta}$ that minimized the sum of squared differences

between the observed data $y_{t_1}, y_{t_2} \ldots y_{t_{n_d}}$ and the model mean $f(t, \Theta)$. We then selected the

C_{thr} and other associated parameters based on which led to the smallest sum of squared errors.

That is, $\Theta = \left(C_{thr}, r_1, p_1, K_{0_1}, \ldots, r_n, p_n, K_{0_n} \right)$ was estimated by $\hat{\Theta} = arg\ min\ \sum_{j=1}^{n_d}(f(t_j, \Theta) -$

$ytj)2$. Finally, we selected the top-ranked sub-epidemic by the corrected Akaike Information

Criterion (AIC_c) values of the set of best-fit models based on one and two sub-epidemics as

discussed below.

Parametric bootstrapping

We quantified parameter uncertainty using a bootstrapping approach described in ref [49] which

allows the computation of standard errors and related statistics without closed-form solutions. To

that end, we used the best-fit model, $f(t, \hat{\Theta})$, to generate B-times replicated simulated datasets of

size n_d, where the observation at time t_j is independently sampled from a normal distribution

with mean $f(t_j, \hat{\Theta})$ and variance $\dfrac{\sum_{j=1}^{n_d}(f(t_j,\hat{\Theta})-y_{t_j})^2}{n_d - m}$, where m is the number of parameters with

$m = 3$ for 1 sub-epidemic (i.e., $n = 1$) and $m = (3n) + 1$ for $n > 1$. Then, we refit the model to

each B simulated dataset to re-estimate each parameter. The new parameter estimates for each

realization are denoted by $\hat{\Theta}_b$ where $b = 1,2, \dots, B$. Using the sets of re-estimated parameters

$(\hat{\Theta}_b)$, the empirical distribution of each estimate can be characterized, and the resulting

uncertainty around the model fit was obtained from $f(t, \hat{\Theta}_1), f(t, \hat{\Theta}_2), \dots, f(t, \hat{\Theta}_B)$. We also ran

the calibrated model forward in time to generate short-term forecasts (i.e., 1 to 4 weeks ahead)

with quantified uncertainty, employing the same parametric bootstrapping as above. We used

300 ($B = 300$) bootstrap realizations for this analysis to characterize parameter and forecasting

uncertainty.

Selecting the top-ranked sub-epidemic models

We selected the top-ranked sub-epidemic models by the corrected Akaike Information Criterion

(AIC_c) values of the set of best-fit models based on one and two sub-epidemics. We ranked the

models from best to worst according to their AIC_c values, which is given by [50,51]:

$$AIC_c = n_d \log(SSE) + 2m + \frac{2m(m + 1)}{n_d - m - 1}$$

(5)

where $SSE = \sum_{j=1}^{n_d}(f(t_j, \hat{\theta}) - y_{t_j})^2$, m is the number of model parameters, and n_d is the

number of data points. Parameters from the above formula for AIC_c are estimated from the

nonlinear least-squares fit, which implicitly assumes normal distribution for error. We selected

the top two ranking sub-epidemic models, which were then employed to create an ensemble sub-

epidemic model (i.e., Ensemble (2)) described in detail below.

Constructing ensemble *n*-sub-epidemic models

269   We generated ensemble models from both the unweighted (equally weighted top-ranking

270   models) and weighted combination of the two highest-ranking sub-epidemic models (i.e., top-

271   and second-ranked) as deemed by the AIC_{c_i} for the i-th ranked model where $AIC_{c_1} \leq \cdots \leq AIC_{c_I}$

272   and $i = 1, ..., I$. We compute the weight w_i for the i-th model, $i = 1, ... , I$, as follows:

273
$$w_i = \frac{l_i}{l_1 + l_2 + \cdots + l_I},$$

274   (6)

275   where l_i is the relative likelihood of model i, which is given by $l_i = e^{((AIC_{min} - AIC_i)/2)}$ [52] and

276   hence $w_I \leq \cdots \leq w_1$. For the unweighted model, we use the same weight $w_i = 1/I$ for all

277   models, $i = 1, ... , I$. The prediction intervals based on the ensemble model can be obtained using

278   the bootstrap approach explained above.

Sub-epidemic wave framework (Spatial wave framework)

The sub-epidemic wave, or spatial-wave modeling framework, aggregates linked, overlapping,

synchronous sub-epidemics ("waves") to capture complex disease trajectories of differing shapes

and sizes [18,53]. Thus, the modeling framework is referred to as the "spatial wave" framework.

Similar to the n-sub-epidemic framework, this framework has shown past success in capturing

diverse epidemic waves (i.e., high-level, prolonged epidemic plateaus and multi-peak

trajectories), such as those seen throughout the mpox epidemic (Fig A in S1 Appendix) [18,53].

The mathematical building block for the spatial-wave model is the same 3-parameter GLM

discussed above (1). However, a sub-epidemic wave consists of n-overlapping sub-epidemics

employing the following system of coupled differential equations:

289
$$\frac{dC_i(t)}{dt} = rA_{i-1}(t)C_i(t)^p \left(1 - \frac{C_i(t)}{K_i}\right).$$

290   (7)

The incidence curve of mpox cases is given by $\frac{dC_i(t)}{dt}$, where $C_i(t)$ is the cumulative number of

cases for sub-epidemic i at time t, and K_i is the size of sub-epidemic i, where $i = 1, \ldots, n$. The

indicator parameter $A_i(t)$ is the same as given in (3). Starting from an initial sub-epidemic size

K_0, the size of subsequent sub-epidemics, K_i, decline at rate q following either an exponential or

power-law function as described below. The growth rate per unit of time is represented by r, and

the "scaling of growth" parameter by p. Unlike the equation given in (2), parameters r and p do

not vary across sub-epidemics, and the value of K_i depends on the decline rate q. Hence, a total

of 5 parameters (r, p, C_{thr}, q, K_0) for $i = 1, \ldots, n$ are needed to characterize a sub-epidemic wave

composed of two or more sub-epidemics ($n > 1$), and four are needed when $n = 1$. This

analysis considers a maximum of five sub-epidemics ($n \leq 5$) in the epidemic wave trajectory.

Sub-epidemic decline

In this framework, the size of the subsequent i_{th} sub-epidemic (K_i) remains steady or declines in

response to external factors (i.e., behavior changes or interventions). We considered both

exponential and inverse (power-law) decline functions to model the size of consecutive sub-

epidemics as described below, where the decline function that yields the best model fit is

employed for each forecast period and location.

Exponential decline of sub-epidemic sizes

308   When consecutive sub-epidemics follow exponential decline, K_i is given by:

309
$$K_i = K_0 e^{-q(i-1)}.$$

310   (8)

311   The parameter K_0 is the size of the initial sub-epidemic, and $K_1 = K_0$. If $q = 0$, then the model

312   predicts an epidemic wave composed of sub-epidemics of the same size. When $q > 0$, the

313   epidemic wave is composed of a finite number of sub-epidemics given by n_{tot} which is a

314   function of C_{thr}, q, and K_0:

$$n_{tot} = \left\lfloor -\frac{1}{q} \ln \left(\frac{C_{thr}}{K_0} \right) + 1 \right\rfloor$$

315   (9)

316   where the brackets $\lfloor * \rfloor$ denote the largest integer that is smaller than or equal to *. The total size

317   of the epidemic wave composed of n_{tot} overlapping sub-epidemics has the following closed-

318   form solution:

$$K_{tot} = \sum_{i=1}^{n_{tot}} K_0 e^{-q(i-1)} = \frac{K_0(1 - e^{-qn_{tot}})}{1 - e^{-q}}$$

319   (10)

Inverse (Power-law) decline of sub-epidemic sizes

321   When consecutive sub-epidemics decline according to the inverse function, K_i is given by:

$$K_i = K_0 \left(\frac{1}{i}\right)^q.$$

323   (11)

324   When q > 0, then the total number of sub-epidemics (n_{tot}) comprising the epidemic wave is

325   finite and given by:

$$n_{tot} = \left\lceil \left(\frac{C_{thr}}{K_0}\right)^{-\frac{1}{q}} \right\rceil.$$

327   (12)

328   The total size of an epidemic wave is given by the aggregation of n_{tot} overlapping sub-

329   epidemics:

$$K_{tot} = \sum_{i=1}^{n_{tot}} K_0 \left(\frac{1}{i}\right)^q.$$

331   (13)

Selecting the top-ranked sub-epidemic models

We examined the AIC_c values of the set of best-fit sub-epidemic wave models with different

values of the threshold parameter, C_{thr}, to select the top two ranking sub-epidemic models. The

AIC_c is given by (5), where $m = 5$ when the number of sub-epidemics is greater than one ($n >$

1) and $m = 4$ when working with a single sub-epidemic ($n = 1$). The AIC_c given in (5) for the

parameter estimation assumes nonlinear least-squares fit, which implicitly assumes normal

distribution for error.

Parameter estimation and bootstrapping, construction of the ensemble models, and forecasting

methodologies follow the same procedures explained for the *n*-sub-epidemic model.

Auto-Regressive Integrated Moving Average Models (ARIMA)

The auto regressive integrate moving average (ARIMA) model is a tool for understanding and

predicting future values in a time series. It is commonly employed in forecasting financial [54–

56] and weather [57–59] trends, and have become a standard benchmark in disease forecasting

[17,31,33–37,60,61]. ARIMA models consist of three parts: the auto-regression (AR) part

involving regressing on the most recent values of the series, the moving average (MA) of error

terms occurring contemporaneously and at previous times, and the integration (I) or differencing

to account for the overall trend in the data and to make the time series stable. Without the

differencing part, the ARMA (p, q) model

$$y_t - \phi_1 y_{t-1} - \cdots - \phi_p y_{t-p} = c + \epsilon_t - \theta_1 \epsilon_{t-1} + \cdots + \theta_q \epsilon_{t-q},$$

350   (14)

consists of the AR part of regressing y_t on the lagged values $y_{t-1}, \dots, y_{t-p}$, and the MA part of

the linear combination of errors $\epsilon_t, \epsilon_{t-1}, \dots, \epsilon_{t-q}$, where $\{\epsilon_t\}$ is a white noise process with mean

0 and variance σ^2, and c is a constant. The ARMA model (14) can be used to describe stationary

stochastic process whose joint probability distribution does not change with time. When data

show evidence of non-stationary and the mean changes over time (i.e., trend), a differencing step

(corresponding to the "integrated" [62] part of the model) can be applied one or more times to

eliminate the trend. To difference the data, the difference between consecutive observations is

computed, such as $y_t - y_{t-1}$, and then the ARMA model can be applied to the data after

differencing. This leads to an ARIMA model. Mathematically, an ARIMA (p, d, q) process is

given by:

$$\phi(B)(1 - B)^d y_t = c + \theta(B)\epsilon_t,$$

361   (14*)

where B denotes the backshift operator implying $By_t = y_{t-1}$ and $B(By_t) = B^2 y_t = y_{t-2}$, etc,

$\phi(B) = 1 - \phi_1 B - \cdots - \phi_p B^p$ and p is the order of the AR model, d is the degree of

differencing, $\theta(B) = 1 - \theta_1 B - \cdots - \theta_q B^q$ and the q is the order of the MA model. With this

notation, $\phi(B)y_t = y_t - \phi_1 y_{t-1} - \cdots - \phi_p y_{t-p}$, $\theta(B)\epsilon_t = \epsilon_t - \theta_1 \epsilon_{t-1} + \cdots + \theta_q \epsilon_{t-q}$, and

$(1 - B)^d$ means conducting the differencing d times. The *auto.arima* function in the R package

"forecast" was used to select orders and build the model [63], and the *forecast* function in the R

package "forecast" was used for forecasting [64]. Any negative predicted values were truncated

at zero.

Generalized Additive Models (GAM)

371   Generalized Additive Models (GAM) are an extension of Generalized Linear Models (GLM)

372   models by including a sum of unknown smooth functions of some covariates [65]. They can

373   capture non-linear trends, while maintaining similar levels of model explainability and simplicity

374 seen with GLMs [66]. Specific to our study with time as the only covariate, assuming that y_t has

375 normal distribution, our GAM is given as [66]:

$$y_t = \beta_0 + s(t) + \epsilon_t,$$

376   (15)

377 where $s(.)$ is an unknown smooth function of time, and $\epsilon_t \sim N(0, \sigma^2)$. We used the *gam* function

378 in the R package "mgcv" to fit this model [67], where the smooth function $s(.)$ is represented

379 using basis functions, which are building blocks for creating more complex functions via linear

380 combination. The default setting in the "mgcv" uses basis splines, which are piecewise

381 polynomial functions. Specifically,

$$s(t) = \sum_{k=1}^{k} \beta_k b_k(t),$$

382   (16)

where $\{b_k(.)\}$ represent the basis functions, $\{\beta_k\}$ are the expansion coefficients to be estimated,

and k is the number of basis functions [66]. Here, the number of basis functions varied

depending on the length of calibration data available for a given forecasting period. A discrete

penalty was imposed on the basis coefficients to control the degree of smoothness, and the model

was fitted by solving a penalized least square problem. The generalized cross-validation (GCV)

criterion selected the smoothness tuning parameter. A more detailed description of the model

fitting methodology can be found in [67], and the associated *predict* function was used for

forecasting [68]. Any negative predicted values were truncated at zero.

Facebook's Prophet Model

Facebook's Prophet model [69], initially designed for business-related forecasting, has recently

been applied more frequently across multiple fields, including infectious disease modeling.

Specifically, the model has produced both COVID-19 [60,70,71] and mpox forecasts [31]. The

model's primary assumption is that it is "decomposable", therefore, $y(t)$, the main trend, can be

decomposed into three pieces plus an error term. Thus, the model has the following form:

$$y(t) = g(t) + s(t) + h(t) + \epsilon_t$$

397   (17)

where $g(t)$ is a non-periodic component used for modeling of the overall trend, $s(t)$ is a

periodic component used for modeling of periodic (e.g., monthly, weekly or other seasonal)

changes over time and $h(t)$ is an irregular events component used for modeling of irregular

changes (e.g. holidays or similar events). The component $\square_t$ is an error of the model at time t.

We used the default setting of the R *prophet* function from the "prophet" package where the

model has been implemented as given in [72]. Therefore, we fit the default fits of the model

and assess only the model's forecasting performance. The *predict* function was used for

forecasting from the model fit [68]. Any negative predicted values were truncated at zero. A

more detailed description of the model fitting methodology can be found in [72].

Model evaluation

Forecast performance was evaluated for all the retrospectively generated 1-4 weeks ahead

forecasts utilizing data downloaded the week of August 3rd, 2023. Descriptions of the mean

absolute error (MAE), mean squared error (MSE), 95% prediction interval coverage (95% PI)

and weighted interval score (WIS) metrics, along with Winkler and skill score calculations

used in the evaluation, can be found below.

Performance Metrics

To assess performance, we used the mean absolute error (MAE), the mean squared error

(MSE), the coverage of the 95% prediction interval (95% PI coverage), and the weighted

interval score (WIS). A more detailed description of the performance metrics can be found in

[17].

MAE and MSE were used in assessing deviations of the mean model fit to the observed case

data [73,74]:

$$MAE = \frac{1}{N}\sum_{h=1}^{N}|f(t_h, \hat{\Theta}) - \tilde{y}_{t_h}|,$$

422   (18)

423    $$MSE = \frac{1}{N}\sum_{h=1}^{N}\left(f(t_h, \hat{\Theta}) - \tilde{y}_{t_h}\right)^2,$$

424   (19)

where y_{t_h} represents the originally observed case counts across each study location of the h-time

units ahead forecasts, and t_h denotes the time points for the sample data [73,74].

Model uncertainty was assessed via the 95% prediction interval coverage and WIS. Here, the

95% PI coverage represents the proportion of observed cases that fall within the 95% PI. The

WIS proves quantiles of the predictive forecast distribution by combining a set of interval scores

(IS) from probabilistic forecasts. Only a central (1−α)×100% PI is needed to calculate an IS [73].

See below:

$$IS_\alpha(F, y) = (u - l) + \frac{2}{\alpha} * (l - y) * \mathbf{1}(y < l) + \frac{2}{\alpha} * (y - u) * \mathbf{1}(y > u)$$

432   (20)

433   The indicator function, represented above by $\mathbf{1}$, refers to the fact that $\mathbf{1}(y < l) = 1$ if $y < l$ and 0

434   otherwise. The $\frac{\alpha}{2}$ and $1 - \frac{\alpha}{2}$ quantiles of the forecast F are represented by l and u. The IS consists

435   of three distinct quantities:

436   1. The sharpness of F, given by the width $u - l$ of the central $(1 - \alpha) \times 100\%$ PI.

437   2. A penalty term $\frac{2}{\alpha} * (l - y) * \mathbf{1}(y < l)$ for the observations that fall below the lower end

438   point l of the $(1 - \alpha) \times 100\%$ PI. This penalty term is directly proportional to the

439   distance between y and the lower end l of the PI. The strength of the penalty depends on

440   the level.

441   3. An analogous penalty term $\frac{2}{\alpha} * (y - u) * \mathbf{1}(y > u)$ for the observations falling above the

442   upper limit u of the PI.

443   We report several central PIs at different levels $(1 - \alpha_1) < (1 - \alpha_2) < \cdots < (1 - \alpha_K)$

444   along with the predictive median, m, which can be seen as a central prediction interval at level

445    $1 - \alpha_0 \rightarrow 0$. This is referred to as the WIS, and it can be evaluated as follows:

$$WIS_{\alpha_{0:K}}(F, y) = \frac{1}{K + \frac{1}{2}} * \left(w_0 * |y - m| + \sum_{k=1}^{K} w_k * IS_{\alpha_k}(F, y) \right)$$

$\qquad$ (21)

where, $w_k = \frac{\alpha_k}{2}$ for $k = 1,2, \ldots K$ and $w_0 = \frac{1}{2}$. Hence, WIS can be interpreted as a measure of

how close the entire distribution is to the observation in units on the scale of the observed data

[75,76].

Skill Scores and Winkler Score

We calculated skill scores to compare the proportion of improvement over the established

ARIMA model (baseline model) for average MSE, MAE, and WIS, using the n-sub-epidemic

and spatial-wave frameworks as comparison models. Here, *average* refers to the average metric

over all forecasting periods for each model, location, and forecasting horizon. The formula is as

follows [77]:

$$\frac{Baseline\ Model\ -\ Comparison\ Model}{Baseline\ Model} * 100$$

456 $\qquad$ (22)

457 For 95% PI coverage, we first calculated Winkler scores to allow for the quantification of the

458 proportion improvement over the ARIMA model, using the n-sub-epidemic and spatial-wave

459 frameworks as comparison frameworks. Winkler scores were calculated as follows [77]:

$$W_{\alpha,t} = \begin{cases} (u_{\alpha.t} - l_{\alpha,t}) + \dfrac{2}{\alpha}(l_{\alpha,t} - y_t), & if\ y_t < l_{\alpha,t} \\ (u_{\alpha.t} - l_{\alpha,t}), & if\ l_{\alpha,t} \le y_t \le u_{\alpha,t} \\ (u_{\alpha.t} - l_{\alpha,t}) + \dfrac{2}{\alpha}(y_t - u_{\alpha,t}) & if\ y_t > u_{\alpha,t} \end{cases}$$

$\qquad$ (23)

where $u_{\alpha,t}$ is the upper bound of the 95% PI interval at time t, $l_{\alpha,t}$ is the lower bound at time t,

y_t is the observed mpox case incidence at t, and $\alpha = 0.05$ as we are working with 95% PI

intervals. We then calculated the skill scores (22) for average Winkler scores, where scores are

averaged across all forecasting periods, for each model, location, and forecasting horizon.

We selected the ARIMA model as baseline, as it has been frequently evaluated against other

forecasting methodologies in the context of mpox [31,33–37]. Therefore, its inclusion in skill

score calculations provides a more in-depth quantitative evaluation of the forecasting abilities of

the *n*-sub-epidemic and spatial-wave frameworks against a well-vetted methodology.

R-studio (Version: *4.3.1 (Beagle Scouts)*) and MATLAB (Version: *R2022a*) were used to

produce and evaluate all forecasts. Forecast period specific performance metrics, associated

forecasts, Winkler scores, and all software scripts used to produce and evaluate forecasts will be

available in a public repository upon journal acceptance.

Results

Overall and time-period specific forecast performance

The *n*-sub-epidemic framework outperformed the established statistical (i.e., ARIMA, GAM,

SLR, Prophet) and spatial-wave framework models across most locations. Specifically, the *n*-

sub-epidemic unweighted ensemble was the most successful in Brazil, the United Kingdom, the

US (OWID), and the World. The model was followed in success by the top-ranked (Brazil) and

weighted ensemble (Canada and Spain) models. Nevertheless, the spatial-wave top-ranked model

performed best overall in Germany, the ARIMA model in France, and the GAM in the

US(CDC). More detailed descriptions of location- and metric-specific performance can be found

below.

When looking at model performance across countries during specific epidemic phases (i.e., ascending,

peak, descending, tail-end), the GAM model performed best overall during the ascending phase of the

epidemic regarding average MSE, MAE, and WIS. However, the n-sub-epidemic unweighted ensemble

and second-ranked models performed best most frequently regarding average 95% PI coverage. As the

epidemic peaked and then declined in countries, the n-sub-epidemic framework performed best across

most forecasting metrics. However, the spatial-wave top- and second-ranked models produced the lowest

average WIS during the declining phase most frequently. Finally, as the epidemic settled at low case

levels, the spatial-wave top-ranked model did best, producing the lowest average MSE, MAE, and WIS

most often. The ARIMA model produced the best average 95% PI coverage during the same time frame.

Overall, model performance improved as case levels declined. Supplementary figures B-E include

visualizations of average forecast performance trends across epidemic phases for each country and

performance metric (S1 Appendix).

Country-level performance

Brazil

The n-sub-epidemic framework, specifically the top-ranked and unweighted ensemble models,

performed best overall in Brazil, outperforming other models 44% of the time across

performance metrics and horizons (Figs 1-4). The models were followed closely in success by

the n-sub-epidemic weighted ensemble model (38%) (Figs 1-4). The n-sub-epidemic top-ranked

and weighted ensemble models produced the lowest average MSE (Range: 16,302.0-128,915.5)

and MAE (Range: 86.4-135.0) across most forecasting horizons (Figs 1-2). Both models

improved between 8.5 and 26.8% over the ARIMA model regarding average MSE and 21.0-

33.2% for average MAE. The *n*-sub-epidemic top-ranked model most frequently produced the

lowest average WIS (Range: 57.4-97.5), improving 23.0-30.2% over the ARIMA model (Fig 3).

The *n*-sub-epidemic unweighted model produced the lowest average WIS (56.4), MSE

(14,240.9), and MAE (85.2) during the 1-week forecasting horizon and performed best across all

forecasting horizons regarding 95% PI coverage (Range: 93.8-96.3%) (Figs 1-4). When

comparing average Winkler scores, the *n*-sub-epidemic unweighted ensemble improved 6.3-

44.6% over the ARIMA model. Tables A1 through A5 in S3 Appendix contain the tabulation of

skill scores and performance metrics across epidemic phases, models, and forecasting horizons

for Brazil.

Fig 1. Average Mean Squared Errors (MSE) for each location, model, and forecasting

horizon (weeks of July 21st, 2022-Febraruy 23rd, 2023). A total of 1,008 forecasts were

produced for each model. The graph is shown on the log10 scale. The red bars indicate the best-

performing model at a given location and horizon, and multiple red bars indicate ties between

models. The *n*-sub-epidemic framework performed best most frequently across forecasting

horizons and locations regarding average MSE.

Fig 2. Average Mean Absolute Errors (MAE) for each location, model, and forecasting

horizon (weeks of July 21st, 2022-Febraruy 23rd, 2023). A total of 1,008 forecasts were

produced for each model. The graph is shown on the log10 scale. The red bars indicate the best-

performing model at a given location and horizon, and multiple red bars indicate ties between

models. The *n*-sub-epidemic framework performed best most frequently across forecasting

horizons and locations regarding average MAE.

Fig 3. Weighted Interval Score (WIS) for each location, model, and forecasting horizon

(weeks of July 21st, 2022-Febraruy 23rd, 2023). A total of 1,008 forecasts were produced for

each model. The graph is shown on the log10 scale. The red bars indicate the best-performing

model at a given location and horizon, and multiple red bars indicate ties between models. The *n*-

sub-epidemic framework performed best most frequently across forecasting horizons and

locations regarding average WIS.

Fig 4. Average 95% Prediction Interval Coverage (95% PI coverage) for each location,

model, and forecasting horizon (weeks of July 21st, 2022-Febraruy 23rd, 2023). A total of

1,008 forecasts were produced for each model. The red bars indicate the best-performing model

at a given location and horizon, and multiple red bars indicate ties between models. The *n*-sub-

epidemic unweighted ensemble performed best most frequently across forecasting horizons and

locations regarding average 95% PI coverage.

Canada

The *n*-sub-epidemic weighted ensemble and top-ranked models performed best overall in

Canada, outperforming other models across forecasting horizons and metrics 69% and 56% of

the time, respectively (Figs 1-4). Across all forecasting horizons for average MSE (Range:

103.2-128.9) and MAE (Range: 6.3-6.6), the *n*-sub-epidemic top-ranked and weighted ensemble

models produced the lowest values (Figs 1-2). Both models improved considerably over the

ARIMA model regarding average MSE (Range: 83.6-88.2%) and MAE (Range: 58.8-67.6%).

The success of the *n*-sub-epidemic weighted ensemble model continued for average WIS, as the

model produced the lowest WIS across most forecasting horizons (Range: 4.3-4.5) and improved

between 54.3 and 63.0% over the ARIMA model (Fig 3). However, the ARIMA model

performed best most frequently regarding average 95% PI coverage (Range: 94.25-96.55%).

Tables B1 through B5 in S3 Appendix contain the tabulation of skill scores and performance

metrics across epidemic phases, models, and forecasting horizons for Canada.

France

Unlike the other countries, the ARIMA model outperformed all other models 94% of the time

across forecasting metrics and horizons, followed by the *n*-sub-epidemic top-ranked (6%) and

weighted ensemble (6%) models (Figs 1-4). The ARIMA model produced the lowest average

MSE (Range: 22,986.7-24,413.1), WIS (Range: 61.1-62.3), and closest to 95% PI coverage on

average (Range: 89.7-93.1%) consistently across forecasting horizons (Figs 1-2, 4). Regarding

average MAE, the ARIMA model performed best across most forecasting horizons (Range: 90.5-

93.8), albeit the 1-week horizon where the *n*-sub-epidemic top-ranked (80.9) and weighted

ensemble performed best (80.9)(Fig 2). However, the *n*-sub-epidemic top-ranked and weighted

ensemble models saw minimal improvement over the ARIMA regarding average MAE

(<10%). Tables C1 through C5 in S3 Appendix contain the tabulation of skill scores and

performance metrics across epidemic phases, models, and forecasting horizons for France.

Germany

The spatial wave top-ranked model outperformed the other models 69% of the time across

forecasting horizons and performance metrics, followed by the *n*-sub-epidemic (38%)

unweighted ensemble model (Figs 1-4). The spatial-wave top-ranked model produced the lowest

average MSE in the one (559.9) and two-week (514.2) forecasting horizons and across all

forecasting horizons regarding average MAE (Range: 11.0-11.4) and WIS (Range: 7.9-8.3) (Figs

1-3). We also noted considerable improvement in average MSE (Range: 80.0-86.3%), MAE

(Range: 59.1-72.7%), and WIS (Range: 55.1-70.8%) over the ARIMA model. The *n*-sub-

epidemic unweighted ensemble produced the lowest average MSE during the three (563.06) and

four-week (504.64) forecasting horizons, improving 90.1-94.0% over the ARIMA model (Fig 1).

Similarly, the *n*-sub-epidemic unweighted ensemble performed best most frequently regarding

average 95% PI coverage (89.7%), improving 42.8-74.4% over the ARIMA model in average

Winkler scores (Fig 4). Tables D1 through D5 in S3 Appendix contain the tabulation of skill

scores and performance metrics across epidemic phases, models, and forecasting horizons for

Germany.

Spain

The *n*-sub-epidemic framework performed superior in Spain, with the most success noted for the

weighted ensemble model (69%) across forecasting periods and metrics, followed by the top-

ranked model (63%) (Figs 1-4). Regarding average MSE (Range: 9020.3-12,286.1) and MAE

(Range: 46.3-52.4), the *n*-sub-epidemic top-ranked and weighted ensemble models produced the

lowest values across all forecasting horizons (Figs 1-2). Similarly, both models improved

considerably over the ARIMA model regarding average MSE (Range: 25.7-57.4%) and MAE

(Range: 33.2-45.9%). The *n*-sub-epidemic weighted ensemble produced the lowest average WIS

(Range: 33.7-35.4) most frequently across forecasting horizons, improving 19.9-41.6% over the

ARIMA model (Fig 3). The *n*-sub-epidemic second-ranked model performed well regarding

average 95% coverage, producing the closest to 95% coverage across most forecasting horizons

(Range: 94.3-94.8%) (Fig 4). However, the ARIMA model outperformed the *n*-sub-epidemic

second-ranked model across all forecasting horizons regarding Winkler scores. Tables E1

through E5 in S3 Appendix contain the tabulation of skill scores and performance metrics across

epidemic phases, models, and forecasting horizons for Spain.

United Kingdom

Overall, the *n*-sub-epidemic unweighted ensemble model outperformed other models 56% of the

time across forecasting horizons and metrics, followed in success by the top-ranked (25%) and

weighted (25%) ensemble models (Figs 1-4). The *n*-sub-epidemic unweighted ensemble model

produced the lowest average MSE (Range: 2454.9-3012.8) across all forecasting horizons and

for the three- (21.5) and four-week (22.8) horizons regarding average MAE (Figs 1-2). However,

the model saw considerable success over the ARIMA model across all horizons in average MSE

(Range: 45.9-72.1%) and average MAE (Range: 32.1-56.6%). The *n*-sub-epidemic top-ranked

and weighted ensemble produced the lowest average MAE in the one (24.7) and two-week (22.9)

horizons and saw split success across forecasting horizons regarding average WIS (Figs 2-3).

The *n*-sub-epidemic unweighted ensemble performed superior across most forecasting horizons

for average 95% coverage (Fig 4). Tables F1 through F5 in S3 Appendix contain the tabulation

of skill scores and performance metrics across epidemic phases, models, and forecasting

horizons for the United Kingdom.

United States (CDC)

Unlike the other countries, the GAM model performed best in the US (CDC), outperforming the

other models 69% of the time, followed by all models of the spatial-wave framework (25%)

across forecasting horizons and metrics (Figs 1-4). The GAM produced the lowest average MSE

(Range: 32,070.5-352,246.3) and MAE (Range: 95.0-291.3) across all forecasting horizons and

the one-week through three-week forecasting horizons for average WIS (Range: 74.9-179.0)

(Figs 1-3). However, all spatial-wave framework models performed superior across all

forecasting horizons for average 95% PI coverage (Range: 93.1-95.7%), albeit the one-week

horizon where the n-sub-epidemic unweighted ensemble model performed equally well (93.1%)

(Fig 4). However, the ARIMA model outperformed the spatial-wave framework and the n-sub-

epidemic unweighted ensemble model across all forecasting horizons regarding average Winkler

scores. Tables G1 through G5 in S3 Appendix contain the tabulation of skill scores and

performance metrics across epidemic phases, models, and forecasting horizons for the US

(CDC).

United States (OWID)

The n-sub-epidemic unweighted ensemble model performed best across all forecasting horizons

regarding average MSE, MAE, and WIS and across most horizons regarding average 95% PI

coverage, outperforming other models 94% of the time (Figs 1-4). Regarding average MSE, the

model produced values ranging from 31,944.2 to 246,467.4, a 66.0-82.9% improvement over the

ARIMA model (Fig 1). We also observed considerable improvements over the ARIMA model in

average MAE (Range: 50.6-60.9%) and WIS (Range: 45.4-60.8%). The n-sub-epidemic

unweighted ensemble model produced superior average 95% PI coverage across most

forecasting horizons (Range: 87.1-88.5%), improving 27.9-70.5% over the ARIMA model in

average Winkler scores (Fig 4). Tables H1 through H5 in S3 Appendix contain the tabulation of

skill scores and performance metrics across epidemic phases, models, and forecasting horizons

for the US (OWID).

World

The *n*-sub-epidemic unweighted ensemble model, followed by the spatial-wave second-ranked

model, outperformed other models across forecasting horizons and metrics 56% and 31% of the

time, respectively (Figs 1-4). The *n*-sub-epidemic unweighted ensemble model produced the

lowest average MSE (Range: 147,046.3-435,707.3) and MAE (Range: 286.3-362.3) across the

two through four-week forecasting horizons, improving considerably over the ARIMA model

(Figs 1-2). Similarly, the model performed superior regarding average 95% PI coverage most

frequently across forecasting horizons (Range: 93.1-96.6%), albeit the two-week forecasting

horizon where the *n*-sub-epidemic top-ranked model performed best (94.8%) (Fig 4). The *n*-sub-

epidemic unweighted ensemble model improved 37.8-49.3% over the ARIMA model regarding

average Winkler scores. However, the spatial-wave second-ranked model performed best across

most forecasting horizons regarding average WIS (Range: 166.5-297.6), improving 53.5-59.7%

over the ARIMA model (Fig 3). Tables I1 through I5 in S3 Appendix contain the tabulation of

skill scores and performance metrics across epidemic phases, models, and forecasting horizons

for the World.

Discussion

In the context of the global emergency posed by the 2022-2023 mpox epidemic, we have

systematically investigated short-term forecasting performance of multiple models that have

shown competitive performance during epidemics and pandemics and rely on minimal data of

the epidemic's trajectory [16–18]. Overall, the n-sub-epidemic framework, specifically the

unweighted ensemble model, followed by the spatial-wave framework, ARIMA model, and the

GAM, performed best most frequently across locations and forecasting horizons compared to the

other established modeling techniques (e.g., SLR, Prophet).

The n-sub-epidemic framework outperformed other models in Brazil, Canada, Spain, the United

Kingdom, US (OWID) and the World, whereas the spatial-wave framework did best in Germany.

However, France and the US (CDC) behaved uniquely compared to other countries with the

ARIMA model and GAM, respectively, performing best across forecasting horizons. Except in

France and the US (CDC), the spatial-wave and n-sub-epidemic models frequently improved

considerably in each metric, including in average Winkler scores, over the ARIMA model.

Overall, our findings further support the sub-epidemics and ensemble frameworks for forecasting

emerging infectious diseases, especially in the face of limited epidemiological data [17,18].

Although each included location experienced unique epidemic trajectories throughout the mpox

epidemic, the consistent success of the n-sub-epidemic and spatial-wave frameworks highlights

the utility of the aggregated sub-epidemic approach in capturing and producing short-term

forecasts for a wide variety of epidemic trends. For example, the epidemic trajectories of the

mpox epidemic in Canada, the United Kingdom, and the US (OWID) differ considerably.(Fig A

in S1 Appendix). Canada sees multiple peaks in cases throughout the ascending and declining

phases of the epidemic. In contrast, the United Kingdom sees a relatively smooth ascending

phase with a prominent peak during the descending phase, and the US (OWID) sees a mostly

smooth epidemic trajectory without drastic peaks during the ascending or descending phases.

Although different, the n-sub-epidemic unweighted ensemble model performed best across

forecasting horizons for all three locations. Similar observations hold for Germany, Brazil,

Spain, and the World.

France and the US (CDC) behaved differently than the other locations, with the ARIMA

performing best in France and the GAM in the US (CDC). The mpox epidemic in France did not

follow a uni-modal epidemic disease trajectory as seen in other study areas; instead, they

experienced two prominent case peaks with slow ascending and descending phases (Fig A in S1

Appendix). However, throughout the outbreak, large stretches of the epidemic trajectory appear

to form linear trends (i.e., ascending, between peaks, tail-end). As the ARIMA model inherently

assumes linearity, the linear-like trajectory of mpox in France may explain the success of the

ARIMA model in capturing and forecasting the disease's trajectory [78]. Unlike France, the US

(CDC) had little-to-no week-to-week fluctuation, forming a smooth, uni-modal epidemic

trajectory (Fig A in S1 Appendix). The GAM, which performed best in the US (CDC), captures

common non-linear trends, such as in the US (CDC) epidemic trajectory [66]. Therefore, similar

to France, epidemic data following distinctive trajectories may explain the success seen by the

ARIMA and GAM models in France and the US (CDC).

Model performance also differed when looking at specific epidemic phases (i.e., ascending,

peak, descending, and tail-end of the epidemic). For example, across locations, the established

statistical models outperformed other models most frequently during the ascending phase of the

epidemic. Similar to France, the ascending phase for most locations was linear. Therefore, as the

included established statistical techniques are inherently linear, they may best capture the linear-

like trends. However, there were multiple epidemic phases with few forecasting periods

available, limiting the ability to examine country-specific epidemic phase performance in greater

detail.

Finally, the significant success of the n-sub-epidemic unweighted and weighted ensemble models

highlights the utility of ensemble modeling in short-term forecasting [79–87]. Ensemble

modeling has also shown considerable success against individual top-ranking sub-epidemic and

other statistical models in past mpox short-term forecasting efforts [14,16], along with that of

COVID-19 [17,76,84], seasonal influenza [82,87], and Zika [88]. Each ensemble model (e.g.,

weighted, and unweighted) included within the analysis performed competitively at various

forecasting horizons and for different areas. However, the unweighted ensemble n-sub-epidemic

model outperformed all other included models for most locations, demonstrating the continued

competitiveness of ensemble modeling in short-term mpox forecasting.

Our study is not exempt from limitations. We used two sources for weekly time-series

laboratory-confirmed mpox cases, each using varying approaches to compile and disseminate

case information. Similarly, the reporting patterns for countries varied as well. Therefore, the

trends noted above may be a function of reporting delays rather than true case fluctuation.

However, to account for the effect of reporting differences on the observed epidemic trajectories,

we aggregate cases weekly to adjust for within-week reporting delay. Due to the unprecedented

nature of the epidemic and the limited epidemic data available, we examined forecasts derived

from the second-ranked spatial wave and n-sub-epidemic models. Frequently, there was little

statistical support for the second-ranked models relative to the top-ranked model for both

frameworks. The spatial-wave and ensemble n-sub-epidemic frameworks are semi-mechanistic

and provide insight into the natural processes that formed the observed epidemic trends from the

aggregated sub-epidemics. Nevertheless, both frameworks do not account for explicit

mechanisms of reactive behavioral modification and interventions, which likely played a

significant role in controlling the epidemic at local and global levels [6,8]. Finally, current

models are not sensitive to seasonal or event-specific risk behaviors, which limits their

application to short-term forecasts.

In conclusion, our findings further support the competitive performance of the aggregated sub-

epidemic methodologies in producing short-term forecasts within the context of mpox, along

with the utility of ensemble modeling therein producing short-term forecasts. However, the

frameworks could be expanded to other disease types as they have shown utility in short-term

forecasting for epidemiologically different diseases [16–18]. Finally, short-term forecasting tools

are essential in the face of unprecedented pandemics and epidemics. Therefore, further

evaluation and refinements of the spatial-wave and ensemble n-sub-epidemic frameworks could

be achieved via comparison to other models since all the forecasting results are publicly

available to the community for transparency and further investigation.

Acknowledgments

We would like to acknowledge the GSU Advanced Research Computing Technology &

Innovation Core (ARCTIC) team for their help with the development of the mpox forecast

website.

Contributions

A.B., G.C., R.L., and A.K., developed different portions of the code used in analysis. A.B. and

G.C. retrieved and managed data; A.B., and G.C. analyzed the data. A.B., R.L., A.K., and G.C.

wrote the first draft of the manuscript. All authors contributed to writing and revising subsequent

versions of the manuscript. All authors read and approved the final manuscript.

Funding

A.B. is supported by a 2CI fellowship from Georgia State University. G.C. is partially supported

from NSF grants 2125246 and 2026797 and R01 GM 130900.

Competing interests

Authors declare no conflict of interests.

Data availability statement

All original data sources are stated within the paper. Individual forecasts, performance metrics,

and Winkler scores will be made publicly available upon journal acceptance and can be made

available during the peer-review process upon request. Source code for producing and evaluating

the GAM, SLR, ARIMA, and Prophet forecasts will be made publicly available upon journal

acceptance and can be made available during the peer-review process upon request. Source code

for producing and evaluating the ensemble n-sub-epidemic forecasts is publicly available at:

https://github.com/gchowell/ensemble_n-subepidemic_framework. Source code for producing

and evaluating spatial-wave forecasts is publicly available at:

https://github.com/gchowell/spatial_wave_subepidemic_framework.

References

1.   Mathieu E, Spooner F, Dattani S, Ritchie H, Roser M. Mpox (monkeypox) [Internet].

2023 Oct 16 [cited 2023 Oct 16]. Available from: https://ourworldindata.org/monkeypox.

2.   World Health Organization (WHO). Multi-country outbreak of mpox. Geneva (SWTZ):

World Health Organization; 2023 Aug. Report No.: 27.

3.   CDC. Technical report 1: Multi-national mpox outbreak, United States, 2022. Centers for

Disease Control and Prevention. 2023 Feb 27. Available from:

https://www.cdc.gov/poxvirus/mpox/cases-data/technical-report/report-1.html.

4.   Monkeypox declared a global health emergency by the World Health Organization. UN

News. 2022 Jul 23 [cited 2023 Mar 30]. Available from:

https://news.un.org/en/story/2022/07/1123152.

5.   Philpott D, Hughes CM, Alroy KA, Kerins JL, Pavlick J, Asbel L, et al. Epidemiologic

and Clinical Characteristics of Monkeypox Cases - United States, May 17-July 22, 2022.

MMWR Morb Mortal Wkly Rep. 2022;71: 1018–1022. doi:10.15585/mmwr.mm7132e3.

6.   Spicknall IH, Pollock ED, Clay PA, Oster AM, Charniga K, Masters N, et al. Modeling

the Impact of Sexual Networks in the Transmission of Monkeypox virus Among Gay,

Bisexual, and Other Men Who Have Sex with Men - United States, 2022. MMWR Morb

Mortal Wkly Rep. 2022;71: 1131–1135. doi:10.15585/mmwr.mm7135e2.

7.   Hatami H, Jamshidi P, Arbabi M, Safavi-Naini S, Farokh P, Izadi-Jorshari G, et al.

Demographic, epidemiologic, and clinical characteristics of human Monkeypox disease

pre- and post-2022 outbreaks: A systematic review and meta-analysis. Biomedicines.

2023;11: 957. doi:10.3390/biomedicines11030957.

8.   CDC. Technical report 4: Multi-national mpox outbreak, United States, 2022. Centers for

Disease Control and Prevention. 2022 Oct 27. Available from:

https://www.cdc.gov/poxvirus/mpox/cases-data/technical-report/report-4.html.

9.   World Health Organization. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. 2023

Sept 27 [cited 2023 Aug 23]. In: World Health Emergency Dashboard [Internet]. Geneva

(SWTZ): World Health Organization. Available from:

https://worldhealthorg.shinyapps.io/mpx_global/.

10.   Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ, et al.

Heavy-tailed sexual contact networks and monkeypox epidemiology in the global

outbreak, 2022. Science. 2022;378: 90–94. doi:10.1126/science.add4507

11.   Ghazvini K, Keikha M. Human Monkeypox resurgence 2022; a new presentation as a

sexual pathogen. Ann Med Surg (Lond). 2022;80. doi:10.1016/j.amsu.2022.104267.

12.   Rajsri KS, Rao M. A review of Monkeypox: The new global health emergency.

Venereology. 2022;1: 199–211. doi:10.3390/venereology1020014.

13.   Summer-23-Mpox-Forecasts; 2023 [cited 2023 Sep 7]. Database: GitHub [Internet].

Available from: https://github.com/bleicham/Summer-23-Mpox-Forecasts.

14.   Monkeypox forecasting center [Internet]. Atlanta (GA): GSU School of Public Health.

801   c2023 [cited 2023 Sept 7]. Available from: https://publichealth.gsu.edu/research-

802   outreach/monkeypox-forecasting-center/.

803   15.   Monkeypox-usa. 2022 [cited 7 Sep 2023]. Database: GitHub [Internet]. Available from:

804   https://github.com/gchowell/monkeypox-usa.

805   16.   Bleichrodt A, Dahal S, Maloney K, Casanova L, Luo R, Chowell G. Real-time

806   forecasting the trajectory of monkeypox outbreaks at the national and global levels, July-

807   October 2022. BMC Med. 2023;21: 19. doi:10.1186/s12916-022-02725-2.

808   17.   Chowell G, Dahal S, Tariq A, Roosa K, Hyman JM, Luo R. An ensemble n-sub-epidemic

809   modeling framework for short-term forecasting epidemic trajectories: Application to the

810   COVID-19 pandemic in the USA. PLoS Comput Biol. 2022;18: e1010602.

811   doi:10.1371/journal.pcbi.1010602.

812   18.   Chowell G, Tariq A, Hyman JM. A novel sub-epidemic modeling framework for short-

813   term forecasting epidemic waves. BMC Med. 2019;17: 164. doi:10.1186/s12916-019-

814   1406-6.

815   19.   CDC. About flu forecasting [Internet]. Atlanta (GA): Centers for Disease Control and

816   Prevention; 2023 Aug 30 [cited 2023 Sep 12]. Available from:

817   https://www.cdc.gov/flu/weekly/flusight/how-flu-forecasting.htm.

818   20.   WHO. An mpox resurgence in the European Region this spring and summer? To prevent

819   that, key measures must continue. World Health Organization. 2023 May 17 [cited 2023

Sep 12]. Available from: https://www.who.int/europe/news/item/17-05-2023-an-mpox-

resurgence-in-the-european-region-this-spring-and-summer--to-prevent-that--key-

measures-must-continue.

21.   CDC. COVID-19 forecasting and mathematical modeling [Internet]. Atlanta (GA):

Centers for Disease Control and Prevention; 2023 Jun 27 [cited 2023 Sep 12]. Available

from: https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/forecasting-math-

modeling.html.

22.   Panovska-Griffiths J, Watkins NA, Cumming F, Hounsome L, Charlett A, Zhang X-S, et

al. Responsive modelling of the mpox epidemic in England as a cross-government and

academia collaboration: the process, challenges, and lessons learned. Lancet Microbe.

2023;4: e658–e660. doi:10.1016/S2666-5247(23)00151-9.

23.   Kupferschmidt K. Monkeypox cases are plummeting. Scientists are debating why.

Science. 2022 Oct 26 [cited 2023 Sep 12]. Available from:

https://www.science.org/content/article/monkeypox-cases-are-plummeting-scientists-are-

debating-why.

24.   Soucheray S. Global monkeypox cases drop 22%. CIDRAP. 2022 Sep 22 [cited 2023 Sep

12]. Available from: https://www.cidrap.umn.edu/global-monkeypox-cases-drop-22.

25.   Reardon S. What does the future look like for monkeypox? Nature. 2022;610: 250–252.

doi:10.1038/d41586-022-03204-7.

26.   CDC. 2022 mpox outbreak global map [Internet]. Atanta (GA): Centers for Disease

Control and Prevention; 2023 Oct 11 [cited 2023 Oct 16]. Available from:

https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html.

27.   Sample I. Mpox vaccinations extended in London after spike in cases. The Guardian.

2023 Jun 16 [cited 2023 Oct 16]. Available from:

https://www.theguardian.com/world/2023/jun/16/mpox-vaccinations-extended-london-

spike-cases.

28.   Jones AM. Sporadic new mpox cases in Canada have experts urging vaccination ahead of

summer. CTV News. 2023 Apr 19 [cited 2023 Sep 15]. Available from:

https://www.ctvnews.ca/health/sporadic-new-mpox-cases-in-canada-have-experts-urging-

vaccination-ahead-of-summer-1.6362330.

29.   McAndrew T, Majumder MS, Lover AA, Venkatramanan S, Bocchini P, Besiroglu T, et

al. Early human judgment forecasts of human monkeypox, May 2022. Lancet Digit

Health. 2022;4: e569–e571. doi:10.1016/S2589-7500(22)00127-3.

30.   Eid MM, El-Kenawy E-SM, Khodadadi N, Mirjalili S, Khodadadi E, Abotaleb M, et al.

Meta-Heuristic Optimization of LSTM-Based Deep Network for Boosting the Prediction

of Monkeypox Cases. Sci China Ser A Math. 2022;10: 3845. doi:10.3390/math10203845.

31.   Long B, Tan F, Newman M. Forecasting the Monkeypox Outbreak Using ARIMA,

Prophet, NeuralProphet, and LSTM Models in the United States. Forecasting. 2023;5:

127–137. doi:10.3390/forecast5010005.

32. Manohar B, Das R. Artificial neural networks for the prediction of Monkeypox outbreak.

Trop Med Infect Dis. 2022;7: 424. doi:10.3390/tropicalmed7120424.

33. Yasmin F, Hassan MM, Zaman S, Aung ST, Karim A, Azam S. A Forecasting Prognosis

of the Monkeypox Outbreak Based on a Comprehensive Statistical and Regression

Analysis. Computation. 2022;10: 177. doi:10.3390/computation10100177.

34. Qureshi M, Khan S, Bantan RAR, Daniyal M, Elgarhy M, Marzo RR, et al. Modeling and

Forecasting Monkeypox Cases Using Stochastic Models. J Clin Med Res. 2022;11.

doi:10.3390/jcm11216555.

35. Iftikhar H, Khan M, Khan MS, Khan M. Short-term forecasting of Monkeypox cases

using a novel filtering and combining technique. Diagnostics (Basel). 2023;13: 1923.

doi:10.3390/diagnostics13111923.

36. Pramanik A, Sultana S, Rahman MS. Time series analysis and forecasting of Monkeypox

disease using ARIMA and SARIMA model. 2022 13th International Conference on

Computing Communication and Networking Technologies (ICCCNT). IEEE; 2022. pp.

1–7. doi:10.1109/icccnt54827.2022.9984345.

37. Khan MI, Qureshi H, Bae SJ, Awan UA, Saadia Z, Khattak AA. Predicting monkeypox

incidence: Fear is not over! J Infect. 2023;86: 256–308. doi:10.1016/j.jinf.2022.12.021.

38. Brand SPC, Cavallaro M, Cumming F, Turner C, Florence I, Blomquist P, et al. The role

of vaccination and public awareness in forecasts of Mpox incidence in the United

Kingdom. Nat Commun. 2023;14: 1–12. doi:10.1038/s41467-023-38816-8.

39.   Overton CE, Abbott S, Christie R, Cumming F, Day J, Jones O, et al. Nowcasting the

880   2022 mpox outbreak in England. PLoS Comput Biol. 2023;19: e1011463.

881   doi:10.1371/journal.pcbi.1011463.

882   40.   CDC. U.S. mpox case trends reported to CDC [Internet]. Atlanta (GA): Centers for

883   Disease Control and Prevention; 2023 Sep 28 [cited 2023 Oct 16]. Available from:

884   https://www.cdc.gov/poxvirus/mpox/response/2022/mpx-trends.html.

885   41.   Mathieu E, Spooner F, Peters C. Mpox (Monkeypox) Data. 2023 Sep 28 [cited 2023 Aug

886   23]. Database: GitHub [Internet]. Available from: https://github.com/owid/monkeypox.

887   42.   CDC. Case Definitions† for Use in the 2022 Mpox Response [Internet]. Atlanta (GA):

888   Centers for Disease Control and Prevention; 2022 Jul 22 [cited 2023 Oct 16]. Available

889   from: https://www.cdc.gov/poxvirus/mpox/clinicians/case-definition.html.

890   43.   WHO Health Emergencies Programme (WHE). Surveillance, case investigation and

891   contact tracing for mpox (monkeypox): interim guidance, 22 December 2022. Geneva

892   (SWTZ): World Health Organization; 2022 Dec.

893   44.   Chowell G, Hincapie-Palacio D, Ospina J, Pell B, Tariq A, Dahal S, et al. Using

894   Phenomenological Models to Characterize Transmissibility and Forecast Patterns and

895   Final Burden of Zika Epidemics. PLoS Curr. 2016;8.

896   doi:10.1371/currents.outbreaks.f14b2217c902f453d9320a43a35b9583.

897   45.   Pell B, Kuang Y, Viboud C, Chowell G. Using phenomenological models for forecasting

898   the 2015 Ebola challenge. Epidemics. 2018;22: 62–70.

899   doi:10.1016/j.epidem.2016.11.002.

900   46.   Roosa K, Lee Y, Luo R, Kirpich A, Rothenberg R, Hyman JM, et al. Real-time forecasts

901   of the COVID-19 epidemic in China from February 5th to February 24th, 2020. Infect

902   Dis Model. 2020;5: 256–263. doi:10.1016/j.idm.2020.02.002.

903   47.   Roosa K, Lee Y, Luo R, Kirpich A, Rothenberg R, Hyman JM, et al. Short-term forecasts

904   of the COVID-19 epidemic in Guangdong and Zhejiang, China: February 13–23, 2020. J

905   Clin Med. 2020;9: 596. doi:10.3390/jcm9020596.

906   48.   Banks HT, Hu S, Clayton Thompson W. Modeling and Inverse Problems in the Presence

907   of Uncertainty. 1st ed. CRC Press; 2014.

908   49.   Hastie T, Friedman J, Tibshirani R. The Elements of Statistical Learning. 1st ed. New

909   York: Springer; 2001. doi:10.1007/978-0-387-21606-5.

910   50.   Hurvich CM, Tsai C-L. Regression and time series model selection in small samples.

911   Biometrika. 1989;76: 297–307. doi:10.1093/biomet/76.2.297.

912   51.   Sugiura N. Further analysis of the data by Akaike's information criterion and the finite

913   corrections. Commun Stat Theory Methods. 1978;7: 13–26.

914   doi:10.1080/03610927808827599.

915   52.   Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical

916   Information-Theoretic Approach. 2nd ed. New York: Springer; 2003.

917   53.   Chowell G, Rothenberg R, Roosa K, Tariq A, Hyman JM, Luo R. Sub-epidemic model

918   forecasts during the first wave of the COVID-19 pandemic in the USA and European

919   hotspots. Mathematics of Public Health. Cham: Springer International Publishing; 2022.

920   pp. 85–137. doi:10.1007/978-3-030-85053-1_5.

921   54.   Almasarweh M, AL Wadi S. ARIMA Model in Predicting Banking Stock Market Data.

922   Modern Applied Science. 2018;12: 309. doi:10.5539/mas.v12n11p309.

923   55.   Ariyo AA, Adewumi AO, Ayo CK. Stock Price Prediction Using the ARIMA Model.

924   2014 UKSim-AMSS 16th International Conference on Computer Modelling and

925   Simulation. 2014. pp. 106–112. doi:10.1109/UKSim.2014.67.

926   56.   Mondal P, Shit L, Goswami S. Study of effectiveness of time series modeling (ARIMA)

927   in forecasting stock prices. International Journal of Computer Science, Engineering and

928   Applications. 2014;4: 13. doi:10.5121/ijcsea.2014.4202.

929   57.   Dimri T, Ahmad S, Sharif M. Time series analysis of climate variables using seasonal

930   ARIMA approach. J Earth Syst Sci. 2020;129: 149. doi:10.1007/s12040-020-01408-x.

931   58.   Shamsnia SA, Shahidi N, Liaghat A, Sarraf A, Vahdat SF. Modeling of weather

932   parameters using stochastic methods (ARIMA model)(case study: Abadeh Region, Iran).

933   In: IPCBEE [Internet]. International conference on environment and industrial

934   innovation: 2011; Kuala Lumpur, Malaysia. Singapore: IACSIT Press; 2011.

935   59.   Tektaş M. Weather Forecasting Using ANFIS and ARIMA MODELS. EREM. 2010;51:

936   5–10.

937   60.   Aditya Satrio CB, Darmawan W, Nadia BU, Hanafiah N. Time series analysis and

938   forecasting of coronavirus disease in Indonesia using ARIMA model and PROPHET.

939   Procedia Comput Sci. 2021;179: 524–532. doi:10.1016/j.procs.2021.01.036.

940   61.   Wang Y-W, Shen Z-Z, Jiang Y. Comparison of ARIMA and GM(1,1) models for

941   prediction of hepatitis B in China. PLoS One. 2018;13: e0201987.

942   doi:10.1371/journal.pone.0201987.

943   62.   Wikipedia contributors. Order of integration [Internet]. Wikipedia, The Free

944   Encyclopedia. 2022 Mar 24 [cited 2023 Oct 16]. Available from:

945   https://en.wikipedia.org/w/index.php?title=Order_of_integration&oldid=1078913049

946   63.   Hyndman R. auto.arima: Fit best ARIMA model to univariate time series. Version 8.21.1.

947   [cited 2023 Oct 16]. Available from:

948   https://www.rdocumentation.org/packages/forecast/versions/8.21.1/topics/auto.arima

949   64.   Hyndman R. forecast. 2023. Version 8.21.1. [cited 2023 Oct 16]. Available from:

950   https://www.rdocumentation.org/packages/forecast/versions/8.21.1

951   65.   Wood SN. Generalized Additive Models: An Introduction with R, Second Edition. 2nd ed.

952   CRC Press; 2017.

66.   Shafi A. What are Generalised Additive Models? Towards Data Science. 2021 May 18

[cited 2023 Mar 31]. Available from: https://towardsdatascience.com/generalised-

additive-models-6dfbedf1350a.

67.   Wood S. gam: Generalized additive models with integrated smoothness estimation.

Version 1.9-0. [cited 2023 Oct 16]. Available from:

https://www.rdocumentation.org/packages/mgcv/versions/1.9-0/topics/gam.

68.   predict: Model Predictions. Version 3.6.2. [cited 2023 Oct 16]. Available from:

https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/predict

69.   Taylor SJ, Letham B. Forecasting at scale. Am Stat. 2018;72: 37–45.

doi:10.1080/00031305.2017.1380080.

70.   Battineni G, Chintalapudi N, Amenta F. Forecasting of COVID-19 epidemic size in four

high hitting nations (USA, Brazil, India and Russia) by Fb-Prophet machine learning

model. Appl Comput Inform. 2020. doi:10.1108/aci-09-2020-0059.

71.   Kirpich A, Shishkin A, Thomas A, Weppelmann A, Perez Tcher- Nov P, Skums Y.

Excess mortality in belarus during the covid-19 pan- demic as the case study of a country

with limited non-pharmaceutical interventions and limited reporting. Scientific Reports.

2022;12. doi:10.1038/s41598-022-093454-z.

72.   Taylor S. prophet: Prophet forecaster. Version 1.0. 2021 [cited 2023 Oct 16]. Available:

https://www.rdocumentation.org/packages/prophet/versions/1.0/topics/prophet

73. Gneiting T, Raftery AE. Strictly Proper Scoring Rules, Prediction, and Estimation. J Am

Stat Assoc. 2007;102: 359–378. doi:10.1198/016214506000001437.

74. Kuhn M, Johnson K. Applied Predictive Modeling. Springer New York;

doi:10.1007/978-1-4614-6849-3.

75. Bracher J, Ray EL, Gneiting T, Reich NG. Evaluating epidemic forecasts in an interval

format. PLoS Comput Biol. 2021;17: e1008618. doi:10.1371/journal.pcbi.1008618.

76. Cramer EY, Ray EL, Lopez VK, Bracher J, Brennen A, Castro Rivadeneira AJ, et al.

Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in

the United States. Proc Natl Acad Sci U S A. 2022;119: e2113561119.

doi:10.1073/pnas.2113561119.

77. Hyndman RJ, Athanasopoulos G. Forecasting: principles and practice. 3rd ed. OTexts;

2021.

78. Sarkar S. Time series forecasting and analysis: Arima and seasonal-Arima. Analytics

Vidhya. 2020 Apr 4 [cited 2023 Oct 2]. Available from: https://medium.com/analytics-

vidhya/time-series-forecasting-and-analysis-arima-and-seasonal-arima-cacaf61ae863.

79. Reich NG, Lessler J, Funk S, Viboud C, Vespignani A, Tibshirani RJ, et al. Collaborative

hubs: Making the most of predictive epidemic modeling. Am J Public Health. 2022;112:

839–842. doi:10.2105/ajph.2022.306831.

80.   Johansson MA, Apfeldorf KM, Dobson S, Devita J, Buczak AL, Baugher B, et al. An

open challenge to advance probabilistic forecasting for dengue epidemics. Proc Natl

Acad Sci U S A. 2019;116: 24268–24274. doi:10.1073/pnas.1909865116.

81.   Viboud C, Sun K, Gaffey R, Ajelli M, Fumanelli L, Merler S, et al. The RAPIDD ebola

forecasting challenge: Synthesis and lessons learnt. Epidemics. 2018;22: 13–21.

doi:10.1016/j.epidem.2017.08.002.

82.   Reich NG, Brooks LC, Fox SJ, Kandula S, McGowan CJ, Moore E, et al. A collaborative

multiyear, multimodel assessment of seasonal influenza forecasting in the United States.

Proc Natl Acad Sci U S A. 2019;116: 3146–3154. doi:10.1073/pnas.1812594116.

83.   McGowan CJ, Biggerstaff M, Johansson M, Apfeldorf KM, Ben-Nun M, Brooks L, et al.

Collaborative efforts to forecast seasonal influenza in the United States, 2015-2016. Sci

Rep. 2019;9: 683. doi:10.1038/s41598-018-36361-9.

84.   Ray EL, Wattanachit N, Niemi J, Kanji AH, House K, Cramer EY, et al. Ensemble

forecasts of Coronavirus disease 2019 (COVID-19) in the U.s. MedRxiv:

2020.08.19.20177493 [Preprint]. 2020 [cited 2023 Oct 16].

doi:10.1101/2020.08.19.20177493.

85.   Webb CT, Ferrari M, Lindström T, Carpenter T, Dürr S, Garner G, et al. Ensemble

modelling and structured decision-making to support Emergency Disease Management.

Prev Vet Med. 2017;138: 124–133. doi:10.1016/j.prevetmed.2017.01.003.

86.   Arieli I, Babichenko Y, Smorodinsky R. Robust forecast aggregation. Proc Natl Acad Sci

1010   U S A. 2018;115: E12135–E12143. doi:10.1073/pnas.1813934115.

1011   87.   Reich NG, McGowan CJ, Yamana TK, Tushar A, Ray EL, Osthus D, et al. Accuracy of

1012   real-time multi-model ensemble forecasts for seasonal influenza in the U.S. PLoS

1013   Comput Biol. 2019;15: e1007486. doi:10.1371/journal.pcbi.1007486.

1014   88.   Oidtman RJ, Omodei E, Kraemer MUG, Castañeda-Orjuela CA, Cruz-Rivera E,

1015   Misnaza-Castrillón S, et al. Trade-offs between individual and ensemble forecasts of an

1016   emerging infectious disease. Nat Commun. 2021;12: 5379. doi:10.1038/s41467-021-

1017   25695-0.

1018

1019

1020

1021

1022

1023

1024

1025

Supporting Information

S1 Appendix. Visualizations of epidemic trajectories and epidemic phase-specific forecast performance. This file contains multiple figures visualizing the mpox epidemic trajectory in each study location, and average forecast performance for each model across epidemic phases for each study location and performance metric.

S2 Appendix. Sensitivity analysis comparing forecasting performance across different calibration periods. This file contains materials related to the sensitivity analysis conducted to determine the optimal calibration period for the primary analysis.

S3 Appendix. Tabulation of forecasting performance metrics for each model, location, forecasting horizon. This file contains multiple tables that contain average forecast performance metrics for each location, model, forecasting horizon, epidemic phase and the overall average.

Average Mean Absolute Error (MAE) (log10)

Average 95% Prediction Interval Coverage (95% PI Coverage)